Introdução: A modulação da resposta imune em muitas situações clínicas persiste como um dos problemas mais desafiadores em imunologia. Citocinas são fundamentais para esta regulação e são amplamente estudadas. Após a ligação com receptores específicos na superfície das células alvo, uma das principais vias de sinalização é o sistema JAKs/STATs. No entanto, em contraste com as citocinas, não existem estudos detalhados sobre a cinética expressão intracelulares de STAT in vitro. Objetivo: Determinar por citometria de fluxo, a cinética expressão de proteínas STAT 1, 3, 4, 5 e 6 fosforiladas, a produção de citocinas associadas e expressão de seus receptores em PBMC humanas estimuladas in vitro com fito-hemaglutinina (PHA) e antígeno de citomegalovírus (CMV). Metodologia: Foram avaliados CMNs de 23 doadores saudáveis em relação à cinética de expressão STATs (12 doadores estimulados com PHA e 11 estimulados com CMV), secreção de citocinas e expressão de seus receptores. Resultados: Em células estimulada com PHA e CMV, pSTAT1 e 6 tiveram sua expressão aumentada precocemente (4h e três dias, respectivamente). pSTAT3 teve sua expressão aumentada em momentos posteriores (respectivamente 36h e 6 dias). A indução de expressão de pSTAT4 e 5 foi observada nos tempos mais tardios da cinética em células estimuladas com PHA (24-36h), enquanto observamos constante baixo nível de expressão em todos os tempos analisados em células estimuladas com CMV. No que diz respeito á secreção de citocinas em células estimuladas com PHA, níveis maiores de IL-6, IL-10 e IL-4 foram detectados a partir de 12h, enquanto aumento da secreção de IFN-y e IL-2 ocorreu a partir de 24h. Com CMV, apenas IL-6 mostrou um aumento da secreção nos dias 4 e 6. Os receptores de citocinas CD119 (IFN-g), CD126 (IL-6), CD210 (IL-10), CD212 (IL-12), CD25 (IL -2) e CD124 (IL-4) tiveram um aumento da expressão após 24-36h de estimulação com PHA. Com estímulo de CMV, CD126, CD212, CD25, também aumentaram a expressão em tempos tardios (5-6 dias), enquanto os outros receptores mantiveram níveis baixos de expressão em todos os momentos estudados. Discussão: Houve uma correlação entre a cinética de expressão de pSTAT3 e 5, e a cinética das citocinas associadas e de seus receptores (IL-6 / CD126, IL-10 / CD210 e IL-2 / CD25). A cinética de expressão de pSTAT4 se correlacionou com a expressão de CD212. (IL-12p70 não foi detectada no presente estudo). Entretanto a expressão de pSTAT1 e 6 precedeu à de IFN-y / CD119 e IL-4 / CD124. Conclusão: A determinação da cinética de expressão pSTAT in vitro pode contribuir para a compreensão da regulação da resposta imune a patógenos distintos e, potencialmente, ajudar no desenvolvimento de novos alvos terapêuticos bem como de novas estratégias destinadas a modular as vias de sinalização em diversas condições clínicas associadas à desregulação imunológica / Introduction: Modulation of immune responses in many clinical situations persists as one of the most challenging issues in immunology. Cytokines are fundamental to this regulation and have already been extensively studied. After binding with its specific receptors on the surface of the target cells, the main signaling pathway is the JAKs/STATs system. However, in contrast to cytokines, there are no detailed studies on the in vitro intracellular expression kinetics of STATs. Objective: To determine by flow cytometry the kinetics of phosphorylated STAT1, 3, 4, 5 and 6 proteins expression in human PBMCs in vitro stimulated with phytohemagglutinin (PHA) and cytomegalovirus antigen (CMV), and the associated cytokine production and cytokine receptors expression. Methodology: We evaluated PBMCs from 23 healthy donors regarding the kinetics of STATs expression (12 donors stimulated with PHA and 11 stimulated with CMV), cytokine secretion and respective receptors expression. Results: In PHA and CMV stimulated cells, pSTAT 1 and 6 expression increased early, 4h and 3days respectively). pSTAT3 expression augmented at later times (respectively 36h and 6 days). pSTAT4 and 5 expression were observed late in PHA stimulated cells (24-36h), while there was a constantly low level of expression in all times analyzed. Regarding cytokine release In PHA stimulated cells, IL-6, IL10 and IL-4 secretion started to increase at 12h while IFN-y and IL-2 increased at 24h. With CMV, only IL-6 showed increased expression at days 4 and 6. The cytokines receptors CD119 (IFN-g), CD126 (IL-6), CD210 (IL-10), CD212 (IL-12), CD25 (IL-2) and CD124 (IL-4) had increased expression at 24-36h with PHA stimulation. With CMV stimulation, CD126, CD212, CD25 also had increased expression at late times (5-6 days) while the other receptors maintained low expression levels at all times. Discussion: There was a correlation in between the pSTAT3 and 5 expression kinetics and the associated cytokines and cytokine receptors kinetics (IL-6/CD126, IL-10/CD210 and IL-2/CD25. pSTAT4 expression kinetics correlated with that of CD212 expression (IL-12p70 was not detected in the present study). The higher pSTAT1 and 6 expressions preceded that of IFN-y/CD119 and IL-4/CD124, respectively. Conclusion: Determination of pSTAT expression kinetics in vitro can contribute to the understanding of the regulation of immune responses to distinct pathogens and potentially help in the design of new therapeutic targets as well as new strategies aimed at modulating signaling pathways

Introdução: A modulação da resposta imune em muitas situações clínicas persiste como um dos problemas mais desafiadores em imunologia. Citocinas são fundamentais para esta regulação e são amplamente estudadas. Após a ligação com receptores específicos na superfície das células alvo, uma das principais vias de sinalização é o sistema JAKs/STATs. No entanto, em contraste com as citocinas, não existem estudos detalhados sobre a cinética expressão intracelulares de STAT in vitro. Objetivo: Determinar por citometria de fluxo, a cinética expressão de proteínas STAT 1, 3, 4, 5 e 6 fosforiladas, a produção de citocinas associadas e expressão de seus receptores em PBMC humanas estimuladas in vitro com fito-hemaglutinina (PHA) e antígeno de citomegalovírus (CMV). Metodologia: Foram avaliados CMNs de 23 doadores saudáveis em relação à cinética de expressão STATs (12 doadores estimulados com PHA e 11 estimulados com CMV), secreção de citocinas e expressão de seus receptores. Resultados: Em células estimulada com PHA e CMV, pSTAT1 e 6 tiveram sua expressão aumentada precocemente (4h e três dias, respectivamente). pSTAT3 teve sua expressão aumentada em momentos posteriores (respectivamente 36h e 6 dias). A indução de expressão de pSTAT4 e 5 foi observada nos tempos mais tardios da cinética em células estimuladas com PHA (24-36h), enquanto observamos constante baixo nível de expressão em todos os tempos analisados em células estimuladas com CMV. No que diz respeito á secreção de citocinas em células estimuladas com PHA, níveis maiores de IL-6, IL-10 e IL-4 foram detectados a partir de 12h, enquanto aumento da secreção de IFN-y e IL-2 ocorreu a partir de 24h. Com CMV, apenas IL-6 mostrou um aumento da secreção nos dias 4 e 6. Os receptores de citocinas CD119 (IFN-g), CD126 (IL-6), CD210 (IL-10), CD212 (IL-12), CD25 (IL -2) e CD124 (IL-4) tiveram um aumento da expressão após 24-36h de estimulação com PHA. Com estímulo de CMV, CD126, CD212, CD25, também aumentaram a expressão em tempos tardios (5-6 dias), enquanto os outros receptores mantiveram níveis baixos de expressão em todos os momentos estudados. Discussão: Houve uma correlação entre a cinética de expressão de pSTAT3 e 5, e a cinética das citocinas associadas e de seus receptores (IL-6 / CD126, IL-10 / CD210 e IL-2 / CD25). A cinética de expressão de pSTAT4 se correlacionou com a expressão de CD212. (IL-12p70 não foi detectada no presente estudo). Entretanto a expressão de pSTAT1 e 6 precedeu à de IFN-y / CD119 e IL-4 / CD124. Conclusão: A determinação da cinética de expressão pSTAT in vitro pode contribuir para a compreensão da regulação da resposta imune a patógenos distintos e, potencialmente, ajudar no desenvolvimento de novos alvos terapêuticos bem como de novas estratégias destinadas a modular as vias de sinalização em diversas condições clínicas associadas à desregulação imunológica / Introduction: Modulation of immune responses in many clinical situations persists as one of the most challenging issues in immunology. Cytokines are fundamental to this regulation and have already been extensively studied. After binding with its specific receptors on the surface of the target cells, the main signaling pathway is the JAKs/STATs system. However, in contrast to cytokines, there are no detailed studies on the in vitro intracellular expression kinetics of STATs. Objective: To determine by flow cytometry the kinetics of phosphorylated STAT1, 3, 4, 5 and 6 proteins expression in human PBMCs in vitro stimulated with phytohemagglutinin (PHA) and cytomegalovirus antigen (CMV), and the associated cytokine production and cytokine receptors expression. Methodology: We evaluated PBMCs from 23 healthy donors regarding the kinetics of STATs expression (12 donors stimulated with PHA and 11 stimulated with CMV), cytokine secretion and respective receptors expression. Results: In PHA and CMV stimulated cells, pSTAT 1 and 6 expression increased early, 4h and 3days respectively). pSTAT3 expression augmented at later times (respectively 36h and 6 days). pSTAT4 and 5 expression were observed late in PHA stimulated cells (24-36h), while there was a constantly low level of expression in all times analyzed. Regarding cytokine release In PHA stimulated cells, IL-6, IL10 and IL-4 secretion started to increase at 12h while IFN-y and IL-2 increased at 24h. With CMV, only IL-6 showed increased expression at days 4 and 6. The cytokines receptors CD119 (IFN-g), CD126 (IL-6), CD210 (IL-10), CD212 (IL-12), CD25 (IL-2) and CD124 (IL-4) had increased expression at 24-36h with PHA stimulation. With CMV stimulation, CD126, CD212, CD25 also had increased expression at late times (5-6 days) while the other receptors maintained low expression levels at all times. Discussion: There was a correlation in between the pSTAT3 and 5 expression kinetics and the associated cytokines and cytokine receptors kinetics (IL-6/CD126, IL-10/CD210 and IL-2/CD25. pSTAT4 expression kinetics correlated with that of CD212 expression (IL-12p70 was not detected in the present study). The higher pSTAT1 and 6 expressions preceded that of IFN-y/CD119 and IL-4/CD124, respectively. Conclusion: Determination of pSTAT expression kinetics in vitro can contribute to the understanding of the regulation of immune responses to distinct pathogens and potentially help in the design of new therapeutic targets as well as new strategies aimed at modulating signaling pathways

During the course of an immune response, CD4+ T helper cells differentiate into a number of subsets including: T helper 1 (TH1), TH2, TH17, and T follicular helper (TFH) populations. The functional diversity of CD4+ T effector cells results in a coordinated, pathogen-specific immune response. For example, the production of IFNγ by TH1 cells is vital for the clearance of intracellular pathogens, while TFH cell engagement with cognate B cells is required for germinal center (GC) formation and the generation of pathogen- and vaccine- induced antibody production. The development of CD4+ subsets is contingent on extracellular signals, in the form of cytokines, and downstream transcriptional networks responsible for promoting the unique gene expression profile for each subset while simultaneously suppressing alternative cell fates. However, the exact composition of, and stage-specific requirements for, these environmental cytokines and transcription factor networks in the governance of TFH cell differentiation remain incompletely understood. The work in this dissertation seeks to understand how cell-extrinsic cytokine signals and cell-intrinsic transcription factor activities are integrated to properly regulate TFH cell development. Here, we demonstrate that in response to decreased IL-2 and constant IL-12 signaling, T helper 1 (TH1) cells upregulate a TFH-like phenotype, including expression of the TFH lineage defining transcription factor Bcl-6. Intriguingly, our work established that signals from IL-12 were required for both the differentiation and function of this TFH-like population. Mechanistically, IL-12 signals are propagated through both STAT3 and STAT4, leading to the upregulation of the TFH associated genes Bcl6, Il21, and Icos, correlating with increased B cell helper activity. Conversely, exposure of these TFH-like cells to IL-7 results in the STAT5-dependent repression of Bcl-6 and subsequent inhibition of the TFH phenotype. Finally, we describe a novel regulatory mechanism wherein STAT3 and the Ikaros zinc finger transcription factors Ikaros and Aiolos cooperate to regulate Bcl-6 expression in these TFH-like cells. Collectively, the work in this dissertation significantly advances our understanding of the regulatory mechanisms that govern TFH cell differentiation, setting the basis for the rational design of novel immunotherapeutic strategies and increasingly effective vaccines. / Ph. D. / Specialized cells called T helper cells serve as a critical interface between the innate (first line of defense) and adaptive (specialized and long-term) immune systems. During the course of an infection, T helper cells are responsible for orchestrating the immune-mediated elimination of invading viruses, bacteria, and parasites. This wide breadth of functionality is achieved through the formation of distinct T helper subsets including T helper 1 (TH1), TH2, TH17, and T follicular helper (TFH) populations. Individual subsets have distinct developmental requirements and have unique functions within the immune system. For example, TFH cells are required for the production of effective antibodies that recognize invading pathogens, leading to their subsequent elimination. This naturally occurring process is the basis for a number of modern medical therapies including vaccination. Conversely, aberrant generation of antibodies that recognize host tissues can result in the onset of various autoimmune diseases including lupus, multiple sclerosis, and crohn’s disease. Due to the importance of TFH cells to human health, there is intense interest in understanding how these cells are formed. It is recognized that the generation of these therapeutically important immune cells is mediated by numerous cell-extrinsic andintrinsic influences, including proteins in their cellular environment called cytokines, and important proteins inside of the cell called transcription factors. However, as this is a complicated and multi-step process, many questions remain regarding the identity of these cytokines and transcription factors. The work in this dissertation seeks to understand how cellextrinsic cytokine signals and cell-intrinsic transcription factor activities are integrated to properly regulate TFH cell development. Collectively, this body of work significantly advances our understanding of the regulatory mechanisms that govern TFH cell differentiation, setting the basis for the rational design of novel immunotherapeutic strategies and increasingly effective vaccines.

The ability of cells within the adaptive immune system to develop into specialized subsets allow for a robust and tailored immune response in the advent of an infection or injury. Here, CD4+ T-cells are a crucial component within this system, with subsets such as TH1, TH2, TH17, TFH and TREG cells playing vital roles in propagating cell-mediated immunity. For example, TH1 cells are essential in combating intracellular pathogens such as viruses, while TFH cells communicate with B-cells to optimize antibody responses against an invading pathogen. The development (and functionality) of these subsets is ultimately dictated by the appropriate integration of extracellular cues such as cytokines with cell intrinsic transcription factors, thereby promoting the necessary gene profile. Moreover, the observation that T-helper cells could exhibit a flexible nature (i.e having shared gene profiles and effector functions) not only demonstrate the efficiency of our immune system but also how such flexibility could have unintended consequences during adverse events such as autoimmunity. An important mediator of such flexibility is cytokines. However, the complete network of factors that come together to co-ordinate cytokine mediated plasticity remain unknown. Thus, the work in this dissertation hope to delineate the factors that collaborate to regulate cytokine induced T-helper cell flexibility. As such, we see that in the presence of IL-2, the Ikaros Zinc Finger (IkZF) transcription factor Eos is upregulated in TH1 cells, with this factor playing a significant role in promoting regulatory and effector functions of TH1 cells. Moreover, we show that Eos forms a novel protein complex with STAT5 and promotes STAT5 activity in TH1 cells. However, depleting IL-2 from the micro-environment leads to the upregulation of two other members within the IkZF family, Ikaros and Aiolos. Aiolos in turn collaborate with STAT3, induces Bcl-6 expression within these cells, thus promoting these cells to exhibit characteristic features of TFH cells. The work in this dissertation hopes to advance our understanding of the regulatory mechanisms involved in cytokine mediated T-cell flexibility thereby hoping to open new avenues for the development of novel therapeutic strategies in the event of autoimmunity. / Ph. D. / T-helper (TH) cells are an important component of the immune system, as these cells aid in the fight against pathogens by secreting factors that either accentuate the inflammatory response during infection or attenuate immune responses post infection. Such effects are made possible because T-helper cells can differentiate into a variety of subsets, with each subset being an important mediator in maintaining immune homeostasis. For example, the T-helper cell subset called TH1 plays a vital role in the fight against intracellular pathogens such as viruses and certain parasites, while T-follicular helper (TFH) cells aid in the production of antibodies specific to the invading pathogen. The development of such subsets occur when cell extrinsic signals, called cytokines, lead to the activation or induction of cell intrinsic proteins called transcription factors. Interestingly, research over the years have shown that T-helper cells are highly adaptable in nature, with one subset having the ability to attain certain characteristic features of other subsets. This malleable nature of T-helper cells relies on several factors, with cytokines within the micro-environment being an important one. Although this form of flexibility is efficient and beneficial at times, it can also be detrimental, as such flexibility is known to promote certain autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and type 1 diabetes. Such detrimental effects are thought to be due to cytokines within the environment. Therefore understanding how cytokines influence the flexible nature of T-helper cells is important; as controlling such flexibility (either by regulating cytokines or the transcription factors activated as a consequence) could prevent the propagation of undesired T-helper cell functions. As such, the work in this dissertation hopes to uncover how one such cytokine, termed Interleukin-2 (IL-2) mediates the flexibility between TH1 and TFH cells. The work highlighted in this dissertation broadens our understanding of how cytokines influence T-helper cell development and flexibility, and consequently allows the design of novel therapeutic strategies to combat autoimmune diseases.

Resumo: A expressão de citocinas inflamatórias é um processo estritamente regulado por mecanismos variados, incluindo o controle da sinalização intracelular e da atividade transcricional por inibidores endógenos, os quais são pouco estudados e compreendidos. Três grupos de proteínas: SHP, PIAS e SOCS inibem de maneira distinta e específica a transdução de sinais pela via JAK/STAT, bem como a atividade dos fatores de transcrição, eventos que modulam a expressão de diversas citocinas. As doenças periodontais estão associadas à inflamação persistente, com elevados níveis de citocinas proinflamatórias, no entanto praticamente não existem informações sobre a participação destes mecanismos de regulação nas diferentes condições clínicas periodontais. Os objetivos deste projeto incluíram avaliar a cinética de expressão das proteínas SOCS1 e SOCS3 e suas proteínas-alvo, STAT1 e STAT3, respectivamente, durante a evolução da doença periodontal. Foram utilizados 36 ratos Wistar divididos em 2 grupos: DP - doença periodontal induzida por 2 métodos: ligaduras ao redor dos 1os molares inferiores e injeções de 60 μg de LPS de E. coli no tecido gengival palatino dos molares superiores, 3x/semana; Grupo controle negativo - recebeu apenas injeções de PBS (veículo). Os ratos foram sacrificados 7, 15 e 30 dias após a indução da doença periodontal para avaliação histológica e análise macroscópica da perda óssea alveolar. A expressão de SOCS1 e SOCS3 e a ativação de STAT1 e STAT3 foram avaliadas nas biópsias gengivais por PCR em tempo real e Western blot. Ambos os modelos apresentaram significante e progressiva perda óssea dos 7 aos 30 dias. A inflamação foi evidente já no período de 7 dias em ambos os modelos, porém enquanto manteve-se similar nos demais períodos no modelo de indução por LPS, apresentou uma diminuição na severidade da inflamação... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Inflammatory cytokine gene expression is a process strictly regulated by various mechanisms, including the negative regulation of signaling of cytokine receptors and of the activity of transcription factors such as STATs. These mechanisms involve endogenous proteins and are largely unknown, especially in periodontal diseases. Three groups of proteins, SHP, PIAS and SOCS modulate in a fairly specific manner JAK/STAT signaling and/or STAT activity. Periodontal diseases are infectious-inflammatory conditions of the supporting tissues of the teeth associated with increased levels of proinflammatory cytokines, but there are no information regarding the role of these endogenous mediators of JAK/STAT during its course. The aims of this study included the evaluation of the expression kinetics of inducible negative regulators and their target proteins during the course of experimentally induced periodontal disease. 36 Wistar rats were divided into two groups: PD - experimental periodontal disease induced by two methods: ligature placement around the first mandibular molars and E. coli lipopolysaccharide (LPS) injections into the palatal gingival tissues of the maxillary molars, 3x/week, and Negative Control group. Rats were sacrificed 07, 15 and 30 days after disease induction for histological evaluation of periodontal inflammation and macroscopic analysis of alveolar bone loss. SOCS expression and the activation status of STAT1 and STAT3 were evaluated in gingival biopsies by real time PCR and Western Blot. Both disease models presented significant progressive bone loss from 7 to 30 days. Inflammation was evident and similar for all the periods in LPS injected sites; however, a decrease on severity at the end of the experimental period was observed in the ligature model. There was a significant (p<0.05) increase on SOCS1 and SOCS3 gene expression in PD compared to control... (Complete abstract click electronic access below) / Orientador: Joni Augusto Cirelli / Coorientador: Carlos Rossa Junior / Banca: Carlos Ferreira dos Santos / Banca: Paulo Sergio Cerri / Mestre

Made available in DSpace on 2014-06-11T19:28:02Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-03-30Bitstream added on 2014-06-13T19:26:31Z : No. of bitstreams: 1 souza_jac_me_arafo.pdf: 631355 bytes, checksum: 9371a4a7027469c6d4a66de2870a71ed (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A expressão de citocinas inflamatórias é um processo estritamente regulado por mecanismos variados, incluindo o controle da sinalização intracelular e da atividade transcricional por inibidores endógenos, os quais são pouco estudados e compreendidos. Três grupos de proteínas: SHP, PIAS e SOCS inibem de maneira distinta e específica a transdução de sinais pela via JAK/STAT, bem como a atividade dos fatores de transcrição, eventos que modulam a expressão de diversas citocinas. As doenças periodontais estão associadas à inflamação persistente, com elevados níveis de citocinas proinflamatórias, no entanto praticamente não existem informações sobre a participação destes mecanismos de regulação nas diferentes condições clínicas periodontais. Os objetivos deste projeto incluíram avaliar a cinética de expressão das proteínas SOCS1 e SOCS3 e suas proteínas-alvo, STAT1 e STAT3, respectivamente, durante a evolução da doença periodontal. Foram utilizados 36 ratos Wistar divididos em 2 grupos: DP - doença periodontal induzida por 2 métodos: ligaduras ao redor dos 1os molares inferiores e injeções de 60 μg de LPS de E. coli no tecido gengival palatino dos molares superiores, 3x/semana; Grupo controle negativo - recebeu apenas injeções de PBS (veículo). Os ratos foram sacrificados 7, 15 e 30 dias após a indução da doença periodontal para avaliação histológica e análise macroscópica da perda óssea alveolar. A expressão de SOCS1 e SOCS3 e a ativação de STAT1 e STAT3 foram avaliadas nas biópsias gengivais por PCR em tempo real e Western blot. Ambos os modelos apresentaram significante e progressiva perda óssea dos 7 aos 30 dias. A inflamação foi evidente já no período de 7 dias em ambos os modelos, porém enquanto manteve-se similar nos demais períodos no modelo de indução por LPS, apresentou uma diminuição na severidade da inflamação... / Inflammatory cytokine gene expression is a process strictly regulated by various mechanisms, including the negative regulation of signaling of cytokine receptors and of the activity of transcription factors such as STATs. These mechanisms involve endogenous proteins and are largely unknown, especially in periodontal diseases. Three groups of proteins, SHP, PIAS and SOCS modulate in a fairly specific manner JAK/STAT signaling and/or STAT activity. Periodontal diseases are infectious-inflammatory conditions of the supporting tissues of the teeth associated with increased levels of proinflammatory cytokines, but there are no information regarding the role of these endogenous mediators of JAK/STAT during its course. The aims of this study included the evaluation of the expression kinetics of inducible negative regulators and their target proteins during the course of experimentally induced periodontal disease. 36 Wistar rats were divided into two groups: PD - experimental periodontal disease induced by two methods: ligature placement around the first mandibular molars and E. coli lipopolysaccharide (LPS) injections into the palatal gingival tissues of the maxillary molars, 3x/week, and Negative Control group. Rats were sacrificed 07, 15 and 30 days after disease induction for histological evaluation of periodontal inflammation and macroscopic analysis of alveolar bone loss. SOCS expression and the activation status of STAT1 and STAT3 were evaluated in gingival biopsies by real time PCR and Western Blot. Both disease models presented significant progressive bone loss from 7 to 30 days. Inflammation was evident and similar for all the periods in LPS injected sites; however, a decrease on severity at the end of the experimental period was observed in the ligature model. There was a significant (p<0.05) increase on SOCS1 and SOCS3 gene expression in PD compared to control... (Complete abstract click electronic access below)

Mutações inativadoras em homozigose no gene do transdutor de sinal e ativador de transcrição 5B (STAT5B) causam insensibilidade ao hormônio de crescimento associada a disfunção imunológica grave que se manifesta na forma de infecções exacerbadas e de repetição, pneumonia intersticial linfocítica e outros eventos autoimunes. A caracterização do fenótipo destas mutações em heterozigose não foi realizada previamente. Dois pacientes descritos com mutação em homozigose na STAT5B (c.424_427del / p.L142RfsX19) são irmãos brasileiros naturais de Criciúma - Santa Catarina, sem consanguinidade conhecida na família. Houve também o relato de dois outros casos semelhantes na cidade, já falecidos, sugerindo que mutações na STAT5B pudessem ser relativamente frequentes nesta região. Os objetivos deste estudo foram investigar a frequência da mutação c.424_427del da STAT5B na população de Criciúma, avaliar a existência de efeito fundador e caracterizar o efeito da mutação c.424_427del da STAT5B em heterozigose sobre o fenótipo antropométrico e hormonal. Para investigar a frequência desta mutação em Criciúma, 1192 indivíduos da população foram genotipados. Foram identificados sete indivíduos heterozigotos, caracterizando uma frequência alélica mínima de 0,29% (intervalo de confiança 95%: 0,08 a 0,5%), significativamente mais alta que a frequência de outras variantes patogênicas da STAT5B descritas em bases de dados públicas. Utilizando-se o equilíbrio de Hardy-Weinberg, foi possível estimar a incidência de casos de homozigotos para o alelo mutado em um a cada 40 anos. No entanto, utilizando-se a maior frequência possível de acordo com o intervalo de confiança, esta incidência poderia atingir um a cada 13 anos. Além disso, foram estudados os pais dos dois casos relatados como semelhantes aos pacientes homozigotos para mutações na STAT5B e estes pais eram portadores da mutação c.424_427del da STAT5B em heterozigose. Para avaliar o efeito fundador, foram analisados dois marcadores próximos à mutação c.424_427del da STAT5B nos pacientes homozigotos para a mesma, em 33 indivíduos heterozigotos de sete famílias independentes e em 53 indivíduos controles. O mesmo haplótipo estava presente nos pacientes homozigotos para a mutação e em todos os heterozigotos, enquanto em apenas 9,4% dos controles (p < 0,001), apontando a probabilidade de que a mutação c.424_427del nas diferentes famílias tenha sido herdada de um antepassado em comum. Para avaliar o efeito da mutação c.424_427del da STAT5B em heterozigose, foram comparados em conjunto os 33 indivíduos heterozigotos e os 38 familiares não portadores em relação à altura e a alguns exames laboratoriais (gerais e hormonais). Os indivíduos heterozigotos foram significativamente mais baixos, com uma redução na altura de 0,6 desvios-padrão (p= 0,006). Também apresentaram redução significativa dos desvios-padrão de fator de crescimento insulina-símile 1 (IGF-1) e da proteína 3 de ligação a fator de crescimento insulina-símile (IGFBP-3), sem alteração em outros exames. Esses achados mostram que as mutações na STAT5B em heterozigose causam um impacto negativo significativo na altura, mais leve que o visto em pacientes com mutações em homozigose, com altura dentro da variação normal. Esse resultado favorece a hipótese de que variantes patogênicas raras em heterozigose contribuem para a variabilidade da altura normal / Homozygous inactivating mutations in signal transducer and activator of transcription 5B gene (STAT5B) cause growth hormone insensitivity associated with signs of severe immune dysfunction, such as recurrent infections, lymphoid interstitial pneumonia and other autoimmune events. The phenotypic characterization of these mutations in heterozygous state has not been accomplished previously. Two patients with a homozygous STAT5B mutation (c.424_427del / p.L142RfsX19) are Brazilian brothers born in the city of Criciúma, Santa Catarina, and there is not known consanguinity in their family. Moreover, there was a report about two similar cases in this city, already deceased, suggesting that STAT5B mutations could be relatively frequent in this region. The objectives of this study were to evaluate the frequency of STAT5B c.424_427del mutation in Criciúma, to assess the existence of the founder effect and to characterize the effect of heterozygous STAT5B c.424_427del mutation on anthropometric and hormonal phenotypes. To evaluate the frequency of this mutation in Criciúma, 1192 individuals from the population were genotyped. Seven heterozygous individuals were identified, which characterized a minimum allele frequency of 0.29% (95% confidence interval: 0.08 to 0.5%), significantly higher than the frequency of other pathogenic variants described in public databases. By using the Hardy-Weinberg law, it was possible to estimate the incidence of cases of individuals homozygous for this mutation at one every 40 years. However, by using the highest possible frequency according to the confidence interval, this incidence could reach one every 13 years. Additionally, the parents of the two reported cases who were similar to patients with homozygous STAT5B mutations were genotyped and these parents were heterozygous for STAT5B c.424_427del mutation. To assess the founder effect, two markers near the mutation were analyzed in the two boys homozygous for STAT5B c.424_427del mutation, in 33 heterozygous individuals from seven unrelated families and in 53 control individuals. The same haplotype was present in the homozygous boys and in all heterozygous individuals, while in only 9,4% control individuals (p < 0,001), pointing to the probability that STAT5B c.424_427del mutation in different families has been inherited from a common ancestor. To study the effects of heterozygous STAT5B c.424_427del mutation, 33 heterozygous individuals were compared to 38 non-carrier relatives on height and some laboratorial tests. Heterozygous individuals were significantly shorter than their noncarrier relatives, with a height reduction of 0.6 standard deviation scores (p= 0,006). Furthermore, they had a significant reduction in insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) standard deviation scores, without differences in the other exams. These findings show that heterozygous STAT5B mutations cause a significant negative impact on height, milder than the effect seen in patients with homozygous mutations, with height within the normal range. This result favors the hypothesis that rare pathogenic variants in heterozygous state contribute to normal height variability

Poon, Fan Fong. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2009. / Includes bibliographical references (leaves 109-124). / Abstract also in Chinese. / Abstract --- p.i / Acknowledgements --- p.v / Table of Content --- p.vi / List of Figures --- p.xi / List of Tables --- p.xiii / List of Abbreviations --- p.xiv / List of papers published during the study --- p.xvi / Chapter Chapter 1 --- Introduction and Aim of Study --- p.1 / Chapter 1.1 --- General Introduction --- p.1 / Chapter 1.2 --- Project objective and potential significances --- p.6 / Chapter Chapter 2 --- Literature Reviews --- p.8 / Chapter 2.1 --- Cancer genetics --- p.8 / Chapter 2.1.1 --- Oncogenes and TSGs --- p.8 / Chapter 2.1.2 --- Kundsońةs two-hit event of cancer gene --- p.9 / Chapter 2.2 --- Cancer Epigenetics --- p.9 / Chapter 2.2.1 --- Types of Epigenetic regulation --- p.10 / Chapter 2.2.2 --- DNA methylation in TSGs --- p.10 / Chapter 2.2.2.1 --- Promoter CpG island in DNA methylation --- p.10 / Chapter 2.2.2.2 --- Protection system in DNA methylation --- p.11 / Chapter 2.2.2.3 --- Transcriptional silencing by DNA methylation --- p.11 / Chapter 2.2.2.4 --- DNA methylation of TSG silencing in cancers --- p.13 / Chapter 2.2.3 --- Hypomethylation of the cancer genome --- p.14 / Chapter 2.2.4 --- Clinical relevance of cancer epigenetic --- p.14 / Chapter 2.3 --- EGFR/STAT/SOCS pathway --- p.15 / Chapter 2.3.1 --- General Introduction of the EGFR pathway --- p.15 / Chapter 2.3.2 --- EGFR survival signaling pathways --- p.16 / Chapter 2.3.3 --- EGFR/STAT/SOCS signaling --- p.17 / Chapter 2.3.4 --- EGFR/STAT/SOCS signaling and cancers --- p.18 / Chapter 2.3.4.1 --- EGF and cancers --- p.18 / Chapter 2.3.4.2 --- EGFR/STAT/SOCS pathway and cancers --- p.18 / Chapter 2.3.4.3 --- EGF survival signaling as a target for cancer therapy --- p.19 / Chapter 2.4 --- TSGs in the EGFR/STAT/SOCS pathway --- p.20 / Chapter 2.4.1 --- Suppressors of cytokine signaling (SOCS) family --- p.20 / Chapter 2.4.2 --- Signal transducers and activators of transcription (STATs) family --- p.22 / Chapter 2.4.3 --- Sprouty (SPRY) family --- p.23 / Chapter 2.4.4 --- Protein Inhibitor of Activated STAT (PIASs) family --- p.25 / Chapter 2.4.5 --- Ras and Rab Interactor (RIN) family --- p.26 / Chapter 2.4.6 --- Ras-association domain family (RASSF) --- p.26 / Chapter 2.4.7 --- Glycine N-methyltransferase (GNMT) --- p.28 / Chapter 2.5 --- Nasopharyngeal carcinoma (NPC) --- p.30 / Chapter 2.5.1 --- Epidemiology of NPC --- p.30 / Chapter 2.5.2 --- Histopathology of NPC --- p.30 / Chapter 2.5.3 --- Genetic and epigenetic alteration in NPC --- p.31 / Chapter 2.5.4 --- EGFR signaling in NPC --- p.32 / Chapter 2.6 --- Esophageal squamous cell carcinoma (ESCC) --- p.33 / Chapter 2.6.1 --- Epidemiology of ESCC --- p.34 / Chapter 2.6.2 --- Histopathology of ESCC --- p.34 / Chapter 2.6.3 --- Genetic and epigenetic alteration in ESCC --- p.35 / Chapter 2.6.4 --- EGFR signaling in ESCC --- p.36 / Chapter Chapter 3 --- Materials and Methods --- p.38 / Chapter 3.1 --- General Materials --- p.38 / Chapter 3.1.1 --- "Cell lines, tumor and normal tissue samples" --- p.38 / Chapter 3.1.2 --- Maintenance of cell lines --- p.38 / Chapter 3.1.3 --- Drugs treatment of cell lines --- p.39 / Chapter 3.1.4 --- Total RNA extraction --- p.39 / Chapter 3.1.5 --- Genomic DNA extraction --- p.40 / Chapter 3.2 --- General techniques --- p.40 / Chapter 3.2.1 --- Agarose gel electrophoresis of DNA --- p.40 / Chapter 3.2.2 --- TA cloning and blunt end cloning of PCR product --- p.40 / Chapter 3.2.3 --- Transformation of cloning products to E. coli competent cells --- p.41 / Chapter 3.2.4 --- Preparation of plasmid DNA --- p.41 / Chapter 3.2.4.1 --- Mini-prep plasmid DNA extraction --- p.41 / Chapter 3.2.4.2 --- Midi-prep of plasmid DNA --- p.42 / Chapter 3.2.5 --- Measurement of DNA or RNA concentrations --- p.42 / Chapter 3.2.6 --- DNA sequencing of plasmid DNA and PCR products --- p.42 / Chapter 3.3 --- Preparation of reagents and medium --- p.43 / Chapter 3.4 --- Semi-quatitative Reverse-Transcription (RT) PCR expression analysis --- p.44 / Chapter 3.4.1 --- Reverse transcriptin reaction --- p.44 / Chapter 3.4.2 --- Semi-quantitative RT-PCR --- p.44 / Chapter 3.4.2.1 --- Primers design --- p.44 / Chapter 3.4.2.2 --- PCR reaction --- p.46 / Chapter 3.5 --- Methylation analysis of candidate genes --- p.47 / Chapter 3.5.1 --- Bisulfite treatment of genomic DNA --- p.47 / Chapter 3.5.2 --- Methylation-specific PCR (MSP) --- p.48 / Chapter 3.5.2.1 --- Bioinformatics prediction of CpG island --- p.48 / Chapter 3.5.2.2 --- Primers design --- p.48 / Chapter 3.5.2.3 --- PCR reaction --- p.49 / Chapter 3.5.3 --- Bisulfite Genomic Sequencing (BGS) --- p.50 / Chapter 3.6 --- Construction of expression vectors of candidate genes --- p.51 / Chapter 3.6.1 --- Sub-cloning of expression vector of candidate genes --- p.51 / Chapter 3.6.1.1 --- Mouse Socsl expression vector --- p.51 / Chapter 3.6.1.2 --- SPRY1 expression vector --- p.51 / Chapter 3.6.1.3 --- GNMT expression vector --- p.52 / Chapter 3.6.2 --- Restriction digestion of cloning vectors and expression --- p.52 / Chapter 3.6.3 --- Ligation of cloning fragments --- p.53 / Chapter 3.6.4 --- Colony formation assay on monolayer culture --- p.53 / Chapter 3.6.5 --- Statistical analysis --- p.54 / Chapter Chapter 4 --- Screening of candidate TSGs in EGFR pathway --- p.55 / Chapter 5.3.3 --- Restoration of GNMT expression by pharmacological demethylation --- p.89 / Chapter 5.3.4 --- Confirmation of the methylation status of GNMT promoter by BGS --- p.90 / Chapter 5.3.5 --- Methylation status of GNMT in ESCC and NPC primary tumors --- p.90 / Chapter 5.3.6 --- GNMT inhibited the growth of tumor cells in-vitro --- p.90 / Chapter 5.3.7 --- Discussion --- p.95 / Chapter Chapter 6 --- General Discussion --- p.100 / Chapter Chapter 7 --- Summary --- p.105 / Chapter Chapter 8 --- Future Study --- p.107 / Reference --- p.109

The societal burden of autoimmune diseases and donor organ transplant rejection in developed countries reflects the lack of effective immune suppressive drugs. The main objective of my thesis was to develop novel fusion proteins targeting receptors linked to autoimmunity; strategies that will allow the suppression of autoreactive cells while sparing resting lymphocytes. Interleukin (IL) 15 has been demonstrated to exert its effects mainly on activated T-cells triggered via their T-cell receptor (TCR). Since we found that the fusion of granulocyte-macrophage colony stimulating factor (GMCSF) to IL15 - aka GIFT15 - paradoxically leads to aberrant signalling downstream of the IL15R and blocks interferon (IFN)-gamma secretion in a mixed lymphocyte reaction (MLR), we hypothesized to use this fusokine in proof-of-principle cell transplantation models and shown that GIFT15 can indeed block the rejection of allogeneic and xenogeneic cells in immunocompetent mice. Additionally, we found that ex vivo GIFT15 treatment of mouse splenocytes lead to the generation of regulatory B-cells (Bregs). These Bregs express high levels of MHCII, IL10 and are capable to block antigen (Ag)-presentation in vitro as third party bystander cells. Moreover, a single injection of these GIFT15-generated Bregs in mice with pre-developed experimental autoimmune encephalomyelitis (EAE) leads to long lasting remission of disease. / Along those lines, we also found that mesenchymal stromal cells (MSCs) lead to the paracrine conversion of CCL2 to an antagonist form capable of specifically inhibiting plasma cells and activated Th17 cells. This mechanistic insight informed the design of a second class of suppression fusokine. Namely, the fusing of antagonist CCL2 to GMCSF - aka GMME1. We tested its potential use in autoimmune diseases such as EAE and rheumatoid arthritis (RA). We demonstrated that GMME1 leads to asymmetrical signalling and inhibition of plasma cells as well as Th17 EAE/RA-reactive CD4 T-cells. The net outcome of these pharmacological effects is the selective depletion of CCR2-reactive T-cells as demonstrated both in vitro and in vivo. / Overall, our data support the use of our fusion proteins as part of a powerful and specific immunosuppressive strategy either as directly injectable protein biopharmaceuticals or through the ex vivo generation of autologous Bregs in the case of GIFT15.

Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-05-12T13:22:54Z No. of bitstreams: 1 Manuela Torres Andion Vidal Estudo...2015.pdf: 4528048 bytes, checksum: dbdb598bed619445f96ad9d571f8324e (MD5) / Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2015-05-12T13:23:08Z (GMT) No. of bitstreams: 1 Manuela Torres Andion Vidal Estudo...2015.pdf: 4528048 bytes, checksum: dbdb598bed619445f96ad9d571f8324e (MD5) / Made available in DSpace on 2015-05-12T13:23:08Z (GMT). No. of bitstreams: 1 Manuela Torres Andion Vidal Estudo...2015.pdf: 4528048 bytes, checksum: dbdb598bed619445f96ad9d571f8324e (MD5) Previous issue date: 2015 / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / O adenoma pleomórfico (AP), o carcinoma mucoepidermóide (CME) e o carcinoma adenóide cístico (CAC) representam tumores frequentes em glândula salivar. A via de sinalização Sonic Hedgehog (Hh) e o Transdutor de sinal e ativador da transcrição 3 (STAT3) desempenham funções importantes na proliferação celular, favorecendo o desenvolvimento tumoral e a proteína MCM3 tem sido considerada uma nova classe de marcadores de proliferação celular. Portanto, o presente trabalho propõe-se a estudar componentes da via Hh, bem como o STAT3 e o MCM3 em neoplasias de glândula salivar, na tentativa de adicionar informações sobre as características biológicas dessas neoplasias. Foram utilizados 9 casos de AP, 17 casos de CAC e 20 casos de CME e, por meio da técnica imunoistoquímica, realizou-se a detecção das seguintes proteínas: SHH, GLI1, SUFU, HHIP, STAT3 e MCM3. No AP, observou-se alta expressão citoplasmática de SHH e SUFU, e baixa expressão de STAT3 e MCM3. No CAC, observou-se alta expressão de GLI1, HHIP e STAT3 e baixa expressão de SHH, SUFU e MCM3. No CME, observou-se alta expressão de SHH, GLI1, SUFU e HHIP e baixa expressão de STAT3 e MCM3. Quando comparado entre os tipos tumorais, observou-se diferença estatisticamente significante para expressão de SHH (p=0.0064), STAT3 (p=0.0003) e MCM3 (p=0.0257). Ao comparar a marcação parenquimal e estromal, observou-se maior expressão em parênquima para todos os tumores (p<0.05). Em glândula salivar normal, observou-se marcação citoplasmática das células ductais para SHH, GLI1, SUFU e HHIP, uma discreta marcação citoplasmática para STAT3 e ausência de marcação para MCM3. Não foi observada correlação entre a via Hh e STAT3 nos tumores de glândula salivar (p>0.05). Os resultados desse trabalho apontam para uma possível participação da via Hh na morfogênese e no desenvolvimento do AP, CAC e CME, assim como a participação do STAT3 no desenvolvimento do CAC. Em adição, o MCM3 não parece ser um bom marcador de proliferação para tumores de glândula salivar. Sugerimos que novos estudos sejam realizados visando compreender o mecanismo pelo qual a via Hh e o STAT3 promovem o crescimento e progressão desses tumores e identificar inibidores dessas vias. / The pleomorphic adenoma (PA), mucoepidermoid carcinoma (MEC) and the adenoid cystic carcinoma (ACC) are common tumors arising from salivary glands. The Sonic Hedgehog signaling pathway (Hh) and signal transducer and activator of transcription 3 (STAT3) play important roles in cell proliferation, favoring tumor growth. The MCM3 protein has been considered as a novel class of cell proliferation markers. The aim of this investigation was to study components of the Hh pathway, as well as STAT3 and MCM3 in salivary gland neoplasms in an attempt to add information about the biological characteristics of these neoplasms. We used 9 cases of PA, 17 cases of ACC and 20 cases of MEC. Using immunohistochemistry, were investigated: SHH, GLI1, Sufu, HHIP, STAT3 and MCM3. In PA, there was high expression of cytoplasmic SHH and Sufu, and low expression of STAT3 and MCM3. In the ACC, there was high expression of GLI1, HHIP and STAT3 and low expression of SHH, SUFU and MCM3. In the MEC, we observed high expression of SHH, GLI1, SUFU and HHIP and low expression of STAT3 and MCM3. There was a statistically significant difference between SHH (p=0.0064), STAT3 (p=0.0003) and MCM3 (p=0.0257) when all tumors were compared. And a higher expression in parenchyma for all tumors when stroma and parenchyma were compared (p<0.05). In normal salivary gland, ductal segment showed imunolabeling for SHH, GLI1, SUFU and HHIP, a discrete cytoplasmic labeling for STAT3 and MCM3 was negative. No correlation was observed between the Hh pathway and STAT3 in salivary gland tumors (p>0.05). The findings suggest a possible role of Hh pathway in the morphogenesis and development of AP, CAC and CME, as well as the participation of STAT3 in the development of ACC. In addition, the MCM3 did not seem to be a good marker of proliferation for salivary gland tumors. It is important that further studies be conducted to understand the mechanism by which the Hh pathway and the STAT3 promote the growth and progression of these tumors and inhibitors of these pathways might be identified.